Evotec SE (EVOTF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Evotec SE (EVOTF) trades at $6.69 with AI Score 45/100 (Grade C). Evotec SE is a drug discovery and development partner for the pharmaceutical and biotechnology industry. Market cap: $1.19B, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for EVOTF: EVOTF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EVOTF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
EVOTF: the 1 perspectives are evenly split.
How is this calculated? →Evotec SE (EVOTF) Healthcare & Pipeline Overview
Evotec SE, a global drug discovery and development partner, collaborates with pharmaceutical and biotechnology companies across diverse therapeutic areas, including diabetes, oncology, and immunology. Headquartered in Hamburg, Germany, Evotec leverages its research expertise and strategic partnerships to advance pharmaceutical innovation, operating in a competitive landscape with companies like BIOGY and CHIZF.
What Is the Investment Thesis for EVOTF?
Evotec SE presents a mixed investment case. While the company operates in a growing drug discovery and development market and has established partnerships with major pharmaceutical companies, its negative profit margin of -21.0% raises concerns about its financial performance. The company's collaborations with industry giants like Bayer and Pfizer provide revenue streams and validation of its research capabilities. However, the company's P/E ratio of -4.87 indicates it is not currently profitable. Upcoming catalysts include potential milestones from ongoing collaborations and advancements in its therapeutic programs. Investors should carefully weigh the growth potential against the current financial challenges.
Based on FMP financials and quantitative analysis
EVOTF Key Highlights
- Evotec SE operates as a drug discovery and development partner for the pharmaceutical and biotechnology industry.
- The company has collaboration agreements with major pharmaceutical companies, including Bayer AG and Pfizer Inc.
- Evotec SE develops pharmaceutical products in various therapeutic areas, such as diabetes, oncology, and immunology.
- The company's market capitalization is $0.93 billion.
- Evotec SE has a negative profit margin of -21.0%.
Who Are EVOTF's Competitors?
EVOTF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BIOGY BioGaia AB (publ) | $11.00 | +0.00% | $1.11B | 53 |
| CHIZF China Traditional Chinese Medicine Holdings Co. Limited | $0.16 | +0.00% | $821.34M | 44 |
| CMOPF Cosmo Pharmaceuticals N.V. | $83.42 | +0.99% | $1.43B | 49 |
| GNMLF Genomma Lab Internacional, S.A.B. de C.V. | $0.84 | +0.00% | $818.18M | 52 |
| KSPHF Kissei Pharmaceutical Co., Ltd. | $30.28 | +17.50% | $1.26B | 50 |
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EVOTF's Key Strengths?
- Strong partnerships with major pharmaceutical companies.
- Diverse portfolio of drug development programs.
- Expertise in multiple therapeutic areas.
- Established presence in the drug discovery and development market.
What Are EVOTF's Weaknesses?
- Negative profit margin.
- Dependence on collaboration agreements for revenue.
- Exposure to regulatory risks.
- Competition from other drug discovery and development companies.
What Could Drive EVOTF Stock Higher?
- Potential milestone payments from existing collaboration agreements.
- Advancements in proprietary drug development programs.
- Expansion of strategic partnerships with pharmaceutical companies.
- Positive clinical trial results for key drug candidates.
What Are the Key Risks for EVOTF?
- Financial-distress signal — its Altman Z-Score of 0.27 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-24.5%) — the business is not currently generating profit on shareholder capital.
- Failure to achieve milestones in collaboration agreements.
- Competition from other drug discovery and development companies.
- Patent expirations and generic drug competition.
- Regulatory risks and changes in healthcare policies.
- Negative clinical trial results for key drug candidates.
What Are the Growth Opportunities for EVOTF?
- Expansion of Strategic Partnerships: Evotec can expand its network of strategic partnerships with pharmaceutical and biotechnology companies. By forging new collaborations, Evotec can access additional funding, diversify its project portfolio, and leverage the expertise of its partners. The global market for pharmaceutical collaborations is projected to reach billions of dollars, presenting a significant opportunity for Evotec to drive revenue growth and expand its market presence. Timeline: Ongoing.
- Advancement of Proprietary Drug Development Programs: Evotec can accelerate the development of its proprietary drug development programs. By investing in research and clinical trials, Evotec can bring novel therapies to market and generate substantial revenue streams. The global market for new drug approvals is projected to grow significantly, driven by unmet medical needs and technological advancements. Timeline: Ongoing.
- Geographic Expansion into Emerging Markets: Evotec can expand its geographic presence into emerging markets, such as Asia and Latin America. These markets offer significant growth opportunities due to their large populations, increasing healthcare spending, and unmet medical needs. By establishing operations in these regions, Evotec can tap into new revenue streams and diversify its geographic footprint. Timeline: 2-3 years.
- Leveraging Artificial Intelligence and Machine Learning: Evotec can leverage artificial intelligence (AI) and machine learning (ML) technologies to accelerate drug discovery and development. By using AI and ML, Evotec can identify promising drug candidates, optimize clinical trial designs, and improve the efficiency of its research processes. The global market for AI in drug discovery is projected to grow substantially, presenting a significant opportunity for Evotec to enhance its competitive advantage. Timeline: Ongoing.
- Focus on Personalized Medicine: Evotec can focus on developing personalized medicine solutions that are tailored to individual patients. By using genetic and other patient-specific information, Evotec can develop more effective and targeted therapies. The global market for personalized medicine is projected to grow rapidly, driven by advancements in genomics and diagnostics. Timeline: 3-5 years.
What Opportunities Does EVOTF Have?
- Expansion into emerging markets.
- Advancement of proprietary drug development programs.
- Leveraging artificial intelligence and machine learning.
- Focus on personalized medicine.
What Threats Does EVOTF Face?
- Patent expirations.
- Competition from generic drugs.
- Changes in regulatory requirements.
- Economic downturns.
What Are EVOTF's Competitive Advantages?
- Established partnerships with major pharmaceutical companies.
- Expertise in drug discovery and development across various therapeutic areas.
- Proprietary technologies and platforms for drug discovery.
- Strong reputation and track record in the industry.
What Does EVOTF Do?
Evotec SE, established in 1993 and headquartered in Hamburg, Germany, operates as a drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. Originally incorporated as Evotec AG, the company rebranded as Evotec SE in April 2019. Evotec's core business revolves around providing research services and developing pharmaceutical products across a broad spectrum of therapeutic areas. These areas include diabetes and its complications, fibrosis, infectious diseases, central nervous system (CNS) disorders, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. Evotec fosters strategic alliances with leading pharmaceutical companies, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, and Pfizer Inc., among others. These collaborations enable Evotec to leverage its research capabilities and contribute to the development of novel therapies. The company's extensive portfolio of partnerships underscores its position as a key player in the drug discovery and development ecosystem. Evotec's global reach extends to various regions, supporting pharmaceutical innovation on an international scale. With a focus on innovation and collaboration, Evotec continues to advance the development of new treatments for a wide range of diseases.
What Products and Services Does EVOTF Offer?
- Provides drug discovery services to pharmaceutical and biotechnology companies.
- Develops pharmaceutical products in various therapeutic areas.
- Conducts research and development activities.
- Engages in strategic collaborations with industry partners.
- Offers integrated drug discovery solutions.
- Focuses on therapeutic areas like diabetes, oncology, and immunology.
- Utilizes advanced technologies for drug discovery.
How Does EVOTF Make Money?
- Generates revenue through research and development collaborations with pharmaceutical and biotechnology companies.
- Receives milestone payments and royalties from partnered drug development programs.
- Provides fee-for-service research and development services.
- Develops and out-licenses proprietary drug candidates.
What Industry Does EVOTF Operate In?
Evotec SE operates within the drug manufacturing industry, specifically focusing on specialty and generic drugs. The industry is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. The global pharmaceutical market is projected to reach trillions of dollars by 2026, driven by an aging population and increasing prevalence of chronic diseases. Evotec competes with companies like BIOGY, CHIZF, and CMOPF, all vying for market share in drug discovery and development. The company's success depends on its ability to innovate, secure partnerships, and navigate the complex regulatory landscape.
Who Are EVOTF's Key Customers?
- Pharmaceutical companies.
- Biotechnology companies.
- Academic research institutions.
- Government research agencies.
Evotec SE (EVOTF) Valuation Context
Valued at $1.19B, EVOTF is classified as a small-cap stock. Relative to its peer group, EVOTF's quantitative score of 45/100 is roughly in line with the peer average of 50/100.
ROE -25%Key Financial Metrics
Return on equity for Evotec SE stands at -24.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -11.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.68 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -21.3%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 4/9Financial Health
Evotec SE's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.27 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Evotec SE revenue of about $729.8M for fiscal 2026, with EPS near $-0.70. The estimate reflects 8 contributing analysts.
EVOTF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Evotec's strategic partnerships are expanding their reach in the drug discovery space, suggesting future revenue streams. Think of it like Moderna's early collaborations before their mRNA breakthrough.
- Recent insider buying activity indicates confidence from those closest to the company's operations. This mirrors situations like when executives loaded up on Google shares before major product launches.
- The community is buzzing about potential breakthroughs in their research pipeline, creating positive market sentiment. This is similar to the excitement around CRISPR companies a few years back.
- The overall market perception is shifting towards recognizing the value of early-stage drug discovery platforms, benefiting Evotec's long-term prospects. This is akin to the increased investor interest in AI infrastructure providers recently.
Bear Case
- Concerns are rising within the community about the increasing competition in the drug discovery sector. This is reminiscent of the crowded electric vehicle market, where many players are vying for dominance.
- Recent market developments suggest a potential slowdown in biotech funding, which could impact Evotec's ability to secure future deals. This is similar to the funding squeeze faced by many startups during the dot-com bust.
- Insider selling, although not always indicative of negative sentiment, raises questions about short-term expectations. It's like when Bezos sold some Amazon shares, sparking debates despite the company's overall health.
- The community is expressing worries about regulatory hurdles and potential delays in drug approvals. This is comparable to the challenges faced by pharmaceutical companies navigating FDA regulations.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
EVOTF Latest News
-
Evotec Reports Results of the Annual General Meeting 2026
Yahoo! Finance: EVOTF News · Jun 11, 2026
-
Assessing Evotec (XTRA:EVT) Valuation After Recent Share Weakness And Ongoing Losses
Yahoo! Finance: EVOTF News · Jun 9, 2026
-
Evotec Appoints Rui Wang as Head of Global In Silico and AI
Yahoo! Finance: EVOTF News · Jun 2, 2026
-
QuickLogic Posts Downbeat Q1 Results, Joins Resideo Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Yahoo! Finance: EVOTF News · May 13, 2026
EVOTF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EVOTF.
Price Targets
Wall Street price target analysis for EVOTF.
EVOTF MoonshotScore
What does this score mean?
The MoonshotScore rates EVOTF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Evotec Reports Results of the Annual General Meeting 2026
Assessing Evotec (XTRA:EVT) Valuation After Recent Share Weakness And Ongoing Losses
Evotec Appoints Rui Wang as Head of Global In Silico and AI
QuickLogic Posts Downbeat Q1 Results, Joins Resideo Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Leadership: Christian Wojczewski
CEO
Christian Wojczewski serves as the CEO of Evotec SE, managing a workforce of 4766 employees. His background includes extensive experience in the pharmaceutical and healthcare industries. Prior to joining Evotec, Wojczewski held leadership positions at several prominent companies, where he focused on strategic development, operational excellence, and business growth. His expertise spans various areas, including drug development, commercialization, and market access. Wojczewski's experience positions him to lead Evotec in its mission to advance drug discovery and development.
Track Record: Under Christian Wojczewski's leadership, Evotec SE has focused on expanding its collaborations and advancing its drug development programs. Key achievements include securing strategic partnerships with major pharmaceutical companies and driving innovation in therapeutic areas such as diabetes, oncology, and immunology. Wojczewski has also emphasized the importance of leveraging technology and data to accelerate drug discovery and improve patient outcomes. His leadership has contributed to Evotec's growth and its position as a key player in the pharmaceutical industry.
EVOTF OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure and may not meet the minimum listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the lack of regulatory oversight and potential for fraud. Companies in this tier may be newly formed, financially distressed, or have limited operating history. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Increased price volatility.
- Potential for fraud and manipulation.
- Lack of regulatory oversight.
- Verify the company's registration and regulatory filings.
- Review the company's financial statements (if available).
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC Other stocks.
- Check for any red flags or warning signs.
- Consult with a financial advisor.
- Established partnerships with reputable pharmaceutical companies.
- Scientific publications and presentations.
- Patents and intellectual property.
- Experienced management team.
- Focus on innovation and drug development.
Common Questions About EVOTF (Healthcare)
What does Evotec SE do?
Evotec SE operates as a drug discovery and development partner, providing services and expertise to pharmaceutical and biotechnology companies worldwide. The company focuses on identifying and developing new drug candidates across various therapeutic areas, including diabetes, oncology, and immunology. Evotec collaborates with industry partners to advance these drug candidates through preclinical and clinical development, with the goal of bringing innovative therapies to market. The company's business model revolves around generating revenue through research collaborations, milestone payments, and royalties from partnered drug programs.
What do analysts say about EVOTF stock?
Analyst opinions on EVOTF stock are currently mixed, reflecting the company's unique position as a drug discovery and development partner. Key valuation metrics, such as the negative P/E ratio, indicate that the company is not currently profitable. However, analysts recognize Evotec's growth potential, driven by its strategic partnerships and advancements in its drug development programs. Analyst consensus suggests that Evotec's long-term success depends on its ability to secure new collaborations, achieve milestones in existing partnerships, and navigate the complex regulatory landscape. Investors should conduct their own research and consider their risk tolerance before investing in EVOTF stock.
What are the main risks for EVOTF?
Evotec SE faces several key risks inherent to the pharmaceutical industry and its specific business model. One significant risk is the dependence on collaboration agreements for revenue, as failure to secure or maintain these partnerships could negatively impact the company's financial performance. Additionally, Evotec is exposed to regulatory risks, including changes in healthcare policies and drug approval processes. Competition from other drug discovery and development companies also poses a threat. Furthermore, the company's drug development programs are subject to clinical trial risks, such as negative results or delays, which could impact the value of its pipeline.
What are the key factors to evaluate for EVOTF?
Evotec SE (EVOTF) holds an AI score of 45/100 (low). Not financial advice.
How frequently does EVOTF data refresh on this page?
EVOTF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven EVOTF's recent stock price performance?
Evotec SE (EVOTF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong partnerships with major pharmaceutical companies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EVOTF overvalued or undervalued right now?
Valuing Evotec SE (EVOTF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying EVOTF?
Before investing in Evotec SE (EVOTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may be limited due to OTC status.
- AI analysis is pending and may provide further insights.